These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 346088)

  • 1. Platelet transfusion therapy. Optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests.
    Brand A; van Leeuwen A; Eernisse JG; van Rood JJ
    Blood; 1978 May; 51(5):781-8. PubMed ID: 346088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four crossmatch methods to select platelet donors.
    Kakaiya RM; Gudino MD; Miller WV; Sherman LA; Katz AJ; Wakem CJ; Krugman DJ; Klatsky AU; Kiraly TR
    Transfusion; 1984; 24(1):35-41. PubMed ID: 6364475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of compatible platelet donors: a prospective evaluation of three cross-matching techniques.
    Wu KK; Hoak JC; Koepke JA; Thompson JS
    Transfusion; 1977; 17(6):638-43. PubMed ID: 145673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy.
    Brubaker DB; Romine M
    Am J Hematol; 1987 Dec; 26(4):341-52. PubMed ID: 3687931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet crossmatch testing for donor selection.
    Slichter SJ
    Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of in vitro assays in selection of compatible platelet donors.
    Tosato G; Appelbaum FR; Trapani RJ; Dowling R; Deisseroth AB
    Transfusion; 1980; 20(1):47-54. PubMed ID: 7355471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between donor-recipient lymphocytotoxicity and the transfusion response using HLA-matched platelet concentrates.
    Herzig RH; Terasaki PI; Trapani RJ; Herzig GP; Graw RG
    Transfusion; 1977; 17(6):657-61. PubMed ID: 595123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates.
    O'Connell BA; Lee EJ; Rothko K; Hussein MA; Schiffer CA
    Blood; 1992 Jan; 79(2):527-31. PubMed ID: 1730095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet crossmatching with lymphocytotoxicity test: an effective method in alloimmunized Chinese patients.
    Chow MP; Yung CH; Hu HY; Tzeng JL; Lin WM; Lin CK
    Transfusion; 1991 Sep; 31(7):595-9. PubMed ID: 1891789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions.
    Sintnicolaas K; Löwenberg B
    Br J Haematol; 1996 Mar; 92(4):1005-10. PubMed ID: 8616059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
    Heal JM; Blumberg N; Masel D
    Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection.
    Hecht T; Wolf JL; Mraz L; Scott EP; Patz LD
    JAMA; 1982 Nov; 248(18):2301-3. PubMed ID: 6752444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of four methods for platelet compatibility testing.
    McFarland JG; Aster RH
    Blood; 1987 May; 69(5):1425-30. PubMed ID: 3552075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experience of HLA-matched platelet transfusion in patients who are refractory to random donor platelets].
    Sekiguchi S; Mitani T; Ohnuma M; Katoh T; Ikeda H; Nakase T; Morioka M; Sakurada K; Miyazaki T
    Hokkaido Igaku Zasshi; 1988 Jul; 63(4):552-61. PubMed ID: 3220437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience.
    Karlström C; Linjama T; Edgren G; Lauronen J; Wikman A; Höglund P
    Transfusion; 2019 Mar; 59(3):945-952. PubMed ID: 30575964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients.
    Freedman J; Gafni A; Garvey MB; Blanchette V
    Transfusion; 1989; 29(3):201-7. PubMed ID: 2493693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.
    Messerschmidt GL; Makuch R; Appelbaum F; Ungerleider RS; Abrams R; O'Donnell J; Holohan TV; Fontana J; Wright D; Anagnou NP
    Cancer; 1988 Aug; 62(4):795-801. PubMed ID: 3293762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Random donor platelet crossmatching: comparison of four platelet antibody detection methods.
    Freedman J; Garvey MB; Salomon de Friedberg Z; Hornstein A; Blanchette V
    Am J Hematol; 1988 May; 28(1):1-7. PubMed ID: 3285667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid phase platelet crossmatching versus complement dependent lymphocytotoxicity--clinical utility.
    Lane D; Shivji S; Turner AR
    Prog Clin Biol Res; 1990; 337():59-62. PubMed ID: 2353019
    [No Abstract]   [Full Text] [Related]  

  • 20. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
    Levy L; Woodfield DG
    N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.